APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)

NCT04638309 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

MDS
Myelodysplastic Syndromes

Interventions

DRUG: APR-548 + Azacitidine

Sponsor

Aprea Therapeutics